MYGN Myriad Genetics
- 13.250
- -0.570-4.12%
Myriad Genetics News
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?
Myriad Genetics Is Maintained at Underperform by B of A Securities
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $13
Top Premarket Decliners
Express News | Myriad Genetics Inc : Jefferies Cuts Target Price to $13 From $15
Reported Earlier, Myriad Genetics Engages Unitedhealthcare On Pharmacogenetic Testing Policy, Seeks Continued Access To Genesight In 2025
Myriad Genetics Talks With UnitedHealthcare on Insurance Exclusion Might Extend Into 2025
Myriad Genetics: During 3Q Earnings Call Provided Estimate of 2024 Fincl Impact of UNH's Updated Medical Policy, Myriad Reaffirms Estimate >MYGN
Myriad Genetics: Desire Resolution Ahead of Yr-End, But Discussions May Extend Into Early 2025 >MYGN
Myriad Genetics: Engaged in Dialogue With UNH Regarding Clinical Evidence Supporting Myriad's Proprietary and Clinically Differentiated Mental Health Medication Test GeneSight >MYGN
Myriad Genetics Engages With UnitedHealthcare on Access to GeneSight Test Following Policy Update
Express News | Myriad Genetics Provides Update on Discussions With Unitedhealthcare Regarding Medical Policy for Pharmacogenetic Testing
Myriad Genetics Provides Update on Discussions With UnitedHealthcare Regarding Medical Policy for Pharmacogenetic Testing
Express News | Myriad Genetics : Approved an Increase in Size of Board From Eight to Nine Members
Press Release: Myriad Genetics Expands Board of Directors With Election of Mark S. Davis as New Board Member
Express News | Myriad Genetics Expands Board of Directors With Election of Mark S. Davis as New Board Member
Myriad Genetics Initiated at Neutral by UBS
Express News | Myriad Genetics’ Portfolio Elevated by Updated Nccn Prostate Cancer Guidelines
Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
UBS Initiates Myriad Genetics(MYGN.US) With Hold Rating, Announces Target Price $18
No Data